Key Highlights
- Each Matinas common share will convert into a right to receive 0.1 of a Pubco common share.
- After the deal, GH Power shareholders are projected to own about 91 % of Pubco’s common equity, while Matinas investors would hold roughly 9 %.
- Matinas BioPharma Holdings, Inc. And its Ontario‑based parent, Pubco.
Matinas BioPharma Holdings, Inc. And its Ontario‑based parent, Pubco. The agreement outlines a two‑step process that will ultimately result in Matinas becoming a wholly owned subsidiary of Pubco.
Subsequently, the merger subsidiary for Matinas will be merged into Matinas itself, leaving Matinas as a direct subsidiary of Pubco. This tiered structure is designed to satisfy both U.S.
Share Exchange Mechanics
For holders of GH Power securities, each pre‑arrangement common share will be exchanged for Pubco common shares based on a predetermined GH Power Exchange Ratio. Preferred shares will be converted on an as‑converted basis using the same ratio, and any outstanding options or warrants will be assumed and re‑issued in a proportionate manner.
Matinas Share Conversion
Matinas common stock, carrying a par value of $0.0001 per share, is set to automatically convert into a right to receive 0.1 Pubco common share. Preferred securities will follow the same conversion path on an as‑converted basis. Existing stock options will be transformed into substitute options that allow the purchase of Pubco shares in line with the 0.1 conversion factor, with the exercise price adjusted by dividing by 0.1.
Company warrants will be treated similarly, converting into assumed warrants reflecting the same proportional entitlement.
Ownership Impact
Pro forma calculations, before any additional financing, indicate that current Matinas equity holders, including participants in the PIPE financing and warrant inducement, will hold approximately 9 % of Pubco’s common equity on a fully diluted basis. In contrast, GH Power shareholders are projected to control about 91 % of the merged entity. The stock component will be calculated using the average closing price of Matinas common stock on the NYSE over the ten trading days preceding the closing date.
Regulatory and Shareholder Process
A proxy statement, incorporated in an F‑4 registration, will be filed with the SEC to solicit the required shareholder approvals at a special meeting. The filing will also request any NYSE consents needed for the securities issuance associated with the PIPE and warrant arrangements. During the interim period, Matinas is restricted from soliciting or facilitating any acquisition proposals.
Timeline and Conditions
The parties have committed to obtaining all necessary stockholder votes and regulatory clearances before the merger can be consummated. Ownership percentages may be adjusted if either side raises additional capital before the effective dates of the arrangement and merger. The agreement also includes customary closing conditions, such as the delivery of legal opinions and the receipt of any required third‑party consents.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.


_11_19_2026_12_58_12_592184.jpg)



Please wait processing your request...